Starpharma aims to create value through the commercialisation of its proprietary products based on dendrimer nanotechnology.
Starpharma is commercialising products based on its proprietary dendrimer technology. The company hold more than 100 granted dendrimer patents covering a range of classes of this type of molecule.
Starpharma develops and commercialises dendrimer nanotechnology across diverse applications, including:
Products based on Starpharma’s dendrimer technology are already on the market for diagnostics and laboratory reagents through licence arrangements with partners including Siemens and Merck KGaA.
Starpharma holds a central position in the dendrimer IP landscape with a wide portfolio of patents and patent applications covering both the composition and application of dendrimers in pharmaceutical, life-science industrial and other fields.
For more information on IP, please refer to Starpharma's current Annual Report 2013 ( pdf file, 1MB).